NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Syros Pharmaceuticals Inc (F: 0S9)

 
0S9 Technical Analysis
5
As on 16th Sep 2022 0S9 STOCK Price closed @ 0.80 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.76 & Strong Sell for SHORT-TERM with Stoploss of 4.97 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

0S9STOCK Price

Open 0.79 Change Price %
High 0.86 1 Day 0.10 14.29
Low 0.79 1 Week 0.10 14.29
Close 0.80 1 Month -0.08 -9.09
Volume 18532 1 Year -5.50 -87.30
52 Week High 6.35 | 52 Week Low 0.64
 
F Germany Most Active Stocks
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
IMU 0.10 %
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
8S3B 1.73 620.83%
8S3B 1.73 620.83%
SY7P 0.07 600.00%
P9F1 1.75 326.83%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
AETG 0.25 -91.61%
AETG 0.25 -91.61%
 
 
0S9
Daily Charts
0S9
Intraday Charts
Whats New @
Bazaartrend
0S9
Free Analysis
 
0S9 Important Levels Intraday
RESISTANCE0.93
RESISTANCE0.89
RESISTANCE0.86
RESISTANCE0.84
SUPPORT0.76
SUPPORT0.74
SUPPORT0.71
SUPPORT0.67
 
0S9 Forecast October 2024
4th UP Forecast4.21
3rd UP Forecast3.12
2nd UP Forecast2.44
1st UP Forecast1.76
1st DOWN Forecast-0.16
2nd DOWN Forecast-0.84
3rd DOWN Forecast-1.52
4th DOWN Forecast-2.61
 
0S9 Weekly Forecast
4th UP Forecast1.96
3rd UP Forecast1.59
2nd UP Forecast1.36
1st UP Forecast1.13
1st DOWN Forecast0.47
2nd DOWN Forecast0.24
3rd DOWN Forecast0.01
4th DOWN Forecast-0.36
 
0S9 Forecast2024
4th UP Forecast11.23
3rd UP Forecast7.88
2nd UP Forecast5.82
1st UP Forecast3.75
1st DOWN Forecast-2.15
2nd DOWN Forecast-4.22
3rd DOWN Forecast-6.28
4th DOWN Forecast-9.63
 
 
0S9 Other Details
Segment EQ
Market Capital 215519184.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
0S9 Address
0S9
 
0S9 Latest News
 
Your Comments and Response on Syros Pharmaceuticals Inc
 
0S9 Business Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. Address: 35 CambridgePark Drive, Cambridge, MA, United States, 02140
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service